NO329401B1 - Fremgangsmate for modifisering av frigjoringshastigheten av en biologisk aktiv forbindelse innkapslet i et multivesikulaert liposom, multivesikulaert liposom samt anvendelse derav. - Google Patents

Fremgangsmate for modifisering av frigjoringshastigheten av en biologisk aktiv forbindelse innkapslet i et multivesikulaert liposom, multivesikulaert liposom samt anvendelse derav. Download PDF

Info

Publication number
NO329401B1
NO329401B1 NO19993635A NO993635A NO329401B1 NO 329401 B1 NO329401 B1 NO 329401B1 NO 19993635 A NO19993635 A NO 19993635A NO 993635 A NO993635 A NO 993635A NO 329401 B1 NO329401 B1 NO 329401B1
Authority
NO
Norway
Prior art keywords
release
neutral lipid
tricaprylin
lipid
triolein
Prior art date
Application number
NO19993635A
Other languages
English (en)
Norwegian (no)
Other versions
NO993635L (no
NO993635D0 (no
Inventor
Randall C Willis
Original Assignee
Pacira Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pacira Pharmaceuticals Inc filed Critical Pacira Pharmaceuticals Inc
Publication of NO993635D0 publication Critical patent/NO993635D0/no
Publication of NO993635L publication Critical patent/NO993635L/no
Publication of NO329401B1 publication Critical patent/NO329401B1/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/829Liposomes, e.g. encapsulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Dispersion Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO19993635A 1997-01-31 1999-07-27 Fremgangsmate for modifisering av frigjoringshastigheten av en biologisk aktiv forbindelse innkapslet i et multivesikulaert liposom, multivesikulaert liposom samt anvendelse derav. NO329401B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/792,566 US5891467A (en) 1997-01-31 1997-01-31 Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes
PCT/US1998/001636 WO1998033483A1 (en) 1997-01-31 1998-01-29 Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes

Publications (3)

Publication Number Publication Date
NO993635D0 NO993635D0 (no) 1999-07-27
NO993635L NO993635L (no) 1999-09-27
NO329401B1 true NO329401B1 (no) 2010-10-11

Family

ID=25157347

Family Applications (2)

Application Number Title Priority Date Filing Date
NO19993635A NO329401B1 (no) 1997-01-31 1999-07-27 Fremgangsmate for modifisering av frigjoringshastigheten av en biologisk aktiv forbindelse innkapslet i et multivesikulaert liposom, multivesikulaert liposom samt anvendelse derav.
NO20100437A NO333827B1 (no) 1997-01-31 2010-03-24 Farmasøytisk preparat og anvendelse derav for forhindring eller forbedring av post-kirurgi eller post-partum smerte.

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20100437A NO333827B1 (no) 1997-01-31 2010-03-24 Farmasøytisk preparat og anvendelse derav for forhindring eller forbedring av post-kirurgi eller post-partum smerte.

Country Status (12)

Country Link
US (2) US5891467A (de)
EP (2) EP0971699B1 (de)
JP (2) JP3940177B2 (de)
AU (1) AU731038B2 (de)
CA (3) CA2692302C (de)
DK (1) DK0971699T3 (de)
ES (1) ES2529167T3 (de)
IL (1) IL131012A0 (de)
NO (2) NO329401B1 (de)
NZ (1) NZ336843A (de)
PT (1) PT971699E (de)
WO (1) WO1998033483A1 (de)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5438075A (en) 1993-03-30 1995-08-01 Skubitz; Keith M. Oral glutamine to reduce stomatitis
JP4467789B2 (ja) 1997-09-18 2010-05-26 パシラ ファーマシューティカルズ インコーポレーテッド 持続放出性リポソーム麻酔組成物
IL135989A0 (en) 1997-11-14 2001-05-20 Skyepharma Inc Processes for the production of multivesicular liposomes
HUP0102741A3 (en) * 1998-10-23 2002-12-28 Idea Ag Method for developing, testing and using associates of macromolecules and complex aggregates for improved payload and controllable de/association rates
CN1320880C (zh) 1998-12-23 2007-06-13 伊迪亚股份公司 改进的体内局部无创伤用制剂
EP1206283A2 (de) 1999-05-17 2002-05-22 Aesgen, Inc. Verbesserte zelluläre aufnahme von bioaktiven wirkstoffen
NZ515644A (en) * 1999-06-04 2004-12-24 Skyepharma Inc Oil-core compositions for the sustained release of hydrophobic drugs
CN1116875C (zh) * 2000-10-19 2003-08-06 南京振中生物工程有限公司 紫杉醇脂质组合物及其制备方法
US20030180348A1 (en) * 2002-03-22 2003-09-25 Levinson R. Saul Transcellular drug delivery system
US20050169979A1 (en) * 2002-07-03 2005-08-04 Dov Michaeli Liposomal vaccine
JP2005535663A (ja) * 2002-07-03 2005-11-24 アフトン コーポレーション リポソームワクチン
US20040247661A1 (en) * 2002-07-03 2004-12-09 Dov Michaeli Liposomal vaccine
JP4664071B2 (ja) * 2002-08-01 2011-04-06 エーザイ コーポレーション オブ ノース アメリカ グルタミンによるガンの改良治療
US20040213837A1 (en) * 2002-08-05 2004-10-28 Sankaram Mantripragada Oil-core compositions for the sustained release of hydrophobic drugs
ITMI20022323A1 (it) * 2002-10-31 2004-05-01 Maria Rosa Gasco Composizioni farmaceutiche atte al trattamento di malattie oftalmiche.
EP1667972B1 (de) 2003-09-10 2013-06-19 Brentwood Equities Ltd. Diastereomere von 4-aryloxy-3-hydroxypiperidinen
ITMI20041151A1 (it) * 2004-06-09 2004-09-09 Maria Rosa Gasco Nanoparticelle lipidiche come agenti veicolanti per acidi nucleici procedimento per la loro preparazione e loro uso
US8338366B2 (en) * 2005-03-14 2012-12-25 The Board of Regents of the University of the Texas System Bioactive FUS1 peptides and nanoparticle-polypeptide complexes
EP1874793A4 (de) * 2005-04-15 2008-12-24 Univ Texas Abgabe von sirna durch neutrale lipid-zusammensetzungen
US20070110674A1 (en) * 2005-07-29 2007-05-17 Yuhong Xu Sono-active liposomes and lipid particles and use thereof as contrast agents and active-agent delivery systems
US20070154546A1 (en) * 2005-12-30 2007-07-05 Zhang Jack Y Sustained release pharmaceutical compositions
WO2008022285A1 (en) * 2006-08-16 2008-02-21 Auspex Pharmaceuticals, Inc. Preparation and utility of opioid analgesics
US8067390B2 (en) * 2007-03-02 2011-11-29 The Board Of Regents Of The University Of Texas System Therapeutic targeting of interleukins using siRNA in neutral liposomes
US8900627B2 (en) * 2008-06-06 2014-12-02 Mirna Therapeutics, Inc. Compositions for the in vivo delivery of RNAi agents
US8293718B2 (en) 2009-12-18 2012-10-23 Novartis Ag Organic compositions to treat HSF1-related diseases
EP2534489A1 (de) 2010-02-10 2012-12-19 Novartis AG Verfahren und verbindungen für muskelwachstum
CN104971672B (zh) * 2010-04-09 2018-01-02 帕西拉制药有限公司 用于配制大直径合成膜囊泡的方法
WO2011131707A1 (en) 2010-04-23 2011-10-27 Novartis Ag ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
US9770414B2 (en) 2010-05-13 2017-09-26 Pacira Pharmaceuticals, Inc. Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent
CN103260702B (zh) 2010-10-28 2018-07-27 帕西拉制药有限公司 非甾体类抗炎药的缓释制剂
JP5813011B2 (ja) 2010-12-27 2015-11-17 テルモ株式会社 リポソーム組成物およびその製造方法
JP2014510045A (ja) 2011-02-08 2014-04-24 ハロザイム インコーポレイテッド ヒアルロナン分解酵素の組成物および脂質製剤ならびに良性前立腺肥大症の治療のためのその使用
EP2741784B1 (de) 2011-03-02 2017-05-17 Board Of Regents, The University Of Texas System Tusc2 therapien
CA2847283C (en) 2011-09-02 2023-03-14 Novartis Ag Organic compositions to treat hsf1-related diseases
GB201119032D0 (en) * 2011-11-03 2011-12-14 Isis Innovation Multisomes: encapsulated droplet networks
US10023862B2 (en) 2012-01-09 2018-07-17 Arrowhead Pharmaceuticals, Inc. Organic compositions to treat beta-catenin-related diseases
EP2844757A2 (de) 2012-05-02 2015-03-11 Novartis AG Organische zusammensetzungen zur behandlung von kras-bedingten erkrankungen
US9668974B2 (en) 2012-05-10 2017-06-06 Painreform Ltd. Depot formulations of a local anesthetic and methods for preparation thereof
CN103565745A (zh) 2012-08-10 2014-02-12 德克萨斯州大学系统董事会 用于治疗中风的神经保护性脂质体组合物和方法
GB201219201D0 (en) 2012-10-25 2012-12-12 Isis Innovation Hydrogel network
GB201219196D0 (en) 2012-10-25 2012-12-12 Isis Innovation Droplet assembly method
KR102449271B1 (ko) 2012-12-07 2022-09-29 옥스포드 유니버시티 이노베이션 리미티드 3d 프린팅에 의한 비말 어셈블리
SG11201506805QA (en) 2013-02-28 2015-09-29 Arrowhead Res Corp Organic compositions to treat epas1-related diseases
CA2902343C (en) 2013-03-14 2022-08-02 Becton Dickinson France S.A.S. Injectable morphine formulations
EP2968729B1 (de) 2013-03-14 2018-08-15 Fresenius Kabi Deutschland GmbH Verpackungssystem für sauerstoffempfindliche medikamenten
US9693958B2 (en) 2013-03-15 2017-07-04 Cureport, Inc. Methods and devices for preparation of lipid nanoparticles
WO2015051135A2 (en) 2013-10-04 2015-04-09 Novartis Ag Organic compositions to treat hepcidin-related diseases
WO2016011123A1 (en) 2014-07-16 2016-01-21 Arrowhead Research Corporation Organic compositions to treat apoc3-related diseases
HUE043847T2 (hu) 2014-08-28 2019-09-30 Halozyme Inc Hialuronán-lebontó enzimmel és egy immun checkpoint inhibitorral végzett kombinációs terápia
US20180010132A1 (en) 2014-09-11 2018-01-11 Novartis Ag Inhibition of prmt5 to treat mtap-deficiency-related diseases
EP3227446A1 (de) 2014-12-01 2017-10-11 Novartis AG Zusammensetzungen und verfahren zur diagnose und behandlung von prostatakrebs
JP6316182B2 (ja) 2014-12-19 2018-04-25 富士フイルム株式会社 リポソームの製造方法及びリポソーム製造装置
US20180296537A1 (en) 2015-06-05 2018-10-18 Novartis Ag Methods and compositions for diagnosing, treating, and monitoring treatment of shank3 deficiency associated disorders
CN106546706B (zh) * 2015-09-21 2020-03-17 上海复旦张江生物医药股份有限公司 pH梯度主动载药法制备的脂质体药物的体外释放测试方法
CN106546705B (zh) * 2015-09-21 2020-03-17 上海复旦张江生物医药股份有限公司 一种脂质体药物体外释放的测试方法
WO2017106814A1 (en) 2015-12-18 2017-06-22 The Board Of Regents Of The University Of Texas System Therapeutics for preterm labor management
BR112018075984A2 (pt) * 2016-06-13 2019-04-02 Ascendia Pharmaceuticals, Llc composição de distribuição de fármaco parenteral para liberação sustentada
WO2018047148A1 (en) 2016-09-12 2018-03-15 Novartis Ag Compounds for the inhibition of mirna
CA3040458A1 (en) 2016-10-12 2018-04-19 Board Of Regents, The University Of Texas System Methods and compositions for tusc2 immunotherapy
EP3535396A1 (de) 2016-11-01 2019-09-11 Novartis AG Verfahren und zusammensetzungen zur verbesserung der genbearbeitung
WO2018094253A1 (en) 2016-11-18 2018-05-24 Pacira Pharmaceuticals, Inc. Zinc meloxicam complex microparticle multivesicular liposome formulations and processes for making the same
KR102069670B1 (ko) * 2017-03-02 2020-01-23 단디바이오사이언스 주식회사 면역활성물질을 포함하는 다중도메인캡슐, 이의 제조방법, 및 이를 포함하는 면역조절 조성물
US11530413B2 (en) 2017-07-21 2022-12-20 Novartis Ag Compositions and methods to treat cancer
CR20200108A (es) 2017-09-11 2020-06-28 Arrowhead Pharmaceuticals Inc Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3)
WO2019150309A1 (en) 2018-02-02 2019-08-08 Hammack Scott Modulators of gpr68 and uses thereof for treating and preventing diseases
EP3788138A1 (de) 2018-05-02 2021-03-10 Novartis AG Regulatoren von menschlichen pluripotenten stammzellen und verwendungen davon
EP3870700A1 (de) 2018-10-24 2021-09-01 Codiak BioSciences, Inc. Verfahren zur verbesserung der potenz der elektroporation
AU2020217747A1 (en) 2019-02-08 2021-09-02 Board Of Regents, The University Of Texas System Telomerase-containing exosomes for treatment of diseases associated with aging and age-related organ dysfunction
EP4138791A1 (de) 2020-04-20 2023-03-01 Board of Regents, The University of Texas System Biologisch aktive trockenpulverzusammensetzungen, verfahren zu deren herstellung und verwendung
US20230302154A1 (en) 2020-08-19 2023-09-28 The Board Of Regents Of The University Of Texas System Nanodrugs for targeted drug delivery and use thereof
US11033495B1 (en) 2021-01-22 2021-06-15 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11357727B1 (en) 2021-01-22 2022-06-14 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11278494B1 (en) 2021-01-22 2022-03-22 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
WO2023225160A1 (en) 2022-05-18 2023-11-23 The Children's Hospital Of Philadelphia Compositions and methods for inducible alternative splicing regulation of gene expression
CN117731835B (zh) * 2023-12-19 2024-08-02 上海花瓣生物科技有限公司 一种含透明质酸钠、琼脂糖微球注射用凝胶的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4078052A (en) 1976-06-30 1978-03-07 The United States Of America As Represented By The Secretary Of Health, Education And Welfare Large unilamellar vesicles (LUV) and method of preparing same
CH624011A5 (de) 1977-08-05 1981-07-15 Battelle Memorial Institute
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
IT1111367B (it) 1978-11-17 1986-01-13 Serono Ist Farm Processo per la preparazione estemporanea di liposomi e liposomi cosi' ottenuti
US4310506A (en) 1979-02-22 1982-01-12 California Institute Of Technology Means of preparation and applications of liposomes containing high concentrations of entrapped ionic species
US4394372A (en) 1980-12-22 1983-07-19 The Procter & Gamble Company Process for making lipid membrane structures
FR2521565B1 (fr) 1982-02-17 1985-07-05 Dior Sa Parfums Christian Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees
US4522803A (en) 1983-02-04 1985-06-11 The Liposome Company, Inc. Stable plurilamellar vesicles, their preparation and use
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
WO1995013796A1 (en) * 1993-11-16 1995-05-26 Depotech Corporation Vesicles with controlled release of actives
US5422120A (en) * 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
US5993850A (en) * 1994-09-13 1999-11-30 Skyepharma Inc. Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances
CA2181390C (en) * 1995-07-18 2001-04-24 Pankaj Modi Phospholipid formulations

Also Published As

Publication number Publication date
NO993635L (no) 1999-09-27
IL131012A0 (en) 2001-01-28
WO1998033483A1 (en) 1998-08-06
CA2277956A1 (en) 1998-08-06
NZ336843A (en) 2001-07-27
JP3940177B2 (ja) 2007-07-04
US5891467A (en) 1999-04-06
CA2277956C (en) 2007-01-23
PT971699E (pt) 2015-02-04
CA2692302A1 (en) 1998-08-06
CA2692302C (en) 2014-05-13
AU6317898A (en) 1998-08-25
NO20100437L (no) 1999-09-27
CA2851502A1 (en) 1998-08-06
AU731038B2 (en) 2001-03-22
JP2001505224A (ja) 2001-04-17
EP0971699A4 (de) 2006-05-24
EP0971699B1 (de) 2014-11-26
JP3973646B2 (ja) 2007-09-12
EP0971699A1 (de) 2000-01-19
EP2322143A1 (de) 2011-05-18
ES2529167T3 (es) 2015-02-17
EP2322143B1 (de) 2017-01-11
DK0971699T3 (en) 2015-02-16
JP2004262946A (ja) 2004-09-24
NO993635D0 (no) 1999-07-27
US5962016A (en) 1999-10-05
NO333827B1 (no) 2013-09-23
CA2851502C (en) 2016-03-15

Similar Documents

Publication Publication Date Title
NO329401B1 (no) Fremgangsmate for modifisering av frigjoringshastigheten av en biologisk aktiv forbindelse innkapslet i et multivesikulaert liposom, multivesikulaert liposom samt anvendelse derav.
US6241999B1 (en) Method for producing liposomes with increased percent of compound encapsulated
EP1098610B1 (de) Biologisch abbaubare anordnungen zur kontrollierten freigabe eingeschlossener substanzen
JP3676976B2 (ja) 多胞状リポソームへの薬剤封入量の調節
DE69535297T2 (de) Zubereitung multivesikulärer liposomen zur gesteuerten freisetzung von wirkstoffen
CA2564120C (en) Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes

Legal Events

Date Code Title Description
MK1K Patent expired